Nippon Soda Co., Ltd. - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Nippon Soda Co., Ltd.


High viscosity grade Nisso HPC-H (hydroxypropyl cellulose) offers advantages as a controlled release polymer when compared to HPMC in a sustained release matrix tablet application. In a direct compression application, HPC-H (fine powder type) sustains drug release more effectively than HPMC in the case of equivalent viscosity of the two polymers. Further, HPC-H has equivalent control release performance to HPMC 100000 while HPC-H has much lower viscosity, and this result is found when the tablet is prepared using either direct compression or wet granulation method.

Fig. 1: Effect of CR material (HPC vs HPMC, direct compression method)

Effect of CR Material (DC Method) is as shown in Fig 1. In the case of DC method, HPC-H-FP sustained drug release more than HPMC 4000, and showed equivalent release control performance to HPMC 100000 while its viscosity was much lower.

Fig 2: Effect of CR Material (HPC vs. HPMC, wet granulation method)

Effect of CR Polymer (WG Method) is as shown in Fig. 2. In the case of WG method, much difference was not seen in comparison of drug release from tablet prepared by HPC-H and HPC-H-FP. Also, Both HPC-H and HPC-H-FP showed equivalent release control performance to HPMC 100000. Drug release from tablet prepared by HPMC 4000 was much faster than the others.

Click here to download a white paper with complete data.

Contact info:
Catherine Cote
c.cote@nissoamerica.com
Nisso America Inc.
88 Pine Street, 14th Fl
New York, NY 10005
+1-212-490-0350
www.nissoexcipients.com

Nisso Chemical Europe GmbH
Naoki Kuwada
kuwada@nisso-chem.de
+49-(0)-211-1306686-0

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
27%
Oversee medical treatment of patients in the US.
9%
Provide treatment for patients globally.
9%
All of the above.
42%
No government involvement in patient treatment or drug development.
12%
Jim Miller Outsourcing Outlook Jim MillerCMO Industry Thins Out
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerFluorination Remains Key Challenge in API Synthesis
Marilyn E. Morris Guest EditorialMarilyn E. MorrisBolstering Graduate Education and Research Programs
Jill Wechsler Regulatory Watch Jill Wechsler Biopharma Manufacturers Respond to Ebola Crisis
Sean Milmo European Regulatory WatchSean MilmoHarmonizing Marketing Approval of Generic Drugs in Europe
FDA Reorganization to Promote Drug Quality
FDA Readies Quality Metrics Measures
New FDA Team to Spur Modern Drug Manufacturing
From Generics to Supergenerics
CMOs and the Track-and-Trace Race: Are You Engaged Yet?

Click here